Benzinga | Jan 11, 2021 08:19AM EST

Sesen Bio Inc Says It Had Cash, Cash Equivalents, And Restricted Cash Of About $55M As Of Dec 31, 2020

On January 11, 2021, Sesen Bio, Inc. (the "Company") disclosed in an updated corporate presentation that it had cash, cash equivalents, and restricted cash of approximately $55 million as of December 31, 2020. This amount is preliminary, has not been audited and is subject to change upon completion of the Company's financial statements for the year ended December 31, 2020. Of note, during 2020 the Company strengthened its balance sheet while minimizing dilution, ahead of the potential FDA approval and commercial launch of Vicineum(tm) in the United States later this year.



The information under this Item 2.02 shall be deemed to be "filed" for the purposes of the Securities Exchange Act of 1934, as amended.